MBIO

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.

Wall Street analysts forecast MBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBIO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mustang Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Mustang Bio Inc. EPS for the last quarter amounts to -0.07 USD, decreased -96.34 % YoY.

Mustang Bio Inc (MBIO) has 6 emplpoyees as of December 15 2025.

Today MBIO has the market capitalization of 8.72M USD.